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Abstract
Introduction. Colorectal cancer (CC) is a malignancy with the third highest incidence and the second cause of death. 1.4 million new cases of colorectal cancer occurred
in 2012, increasing to 1.8 million new cases in 2019, with almost 900,000 deaths caused by CC in the world. In Indonesia, there were 30,017 new cases of CC in 2019,
with fatalities reaching nearly 16,000 cases. There are differences in the survival rates of the CC between developed countries and Indonesia. This study aims to determine
the survival rate of CC patients in Indonesia.
Method. A retrospective cohort study design with survival analysis. The study was conducted at the Department of Surgery, Faculty of Medicine, University of Indonesia,
RSCM, from January 2014 to December 2016. 316 samples were obtained from the registration of the RSC M CC with the CC who had received therapy according to
the stage of cancer they suffered during the period January 2014 to December 2016.
Results. The overall five-year survival rate in this study was 43%. The survival rate of colorectal cancer patients aged ≥45 years reached 50% at observation 20 months.
Age group(95% CI 44.03-57.32) months, stage III was 38.59 months (95% CI 32.20-44.97), 30.36 months in stage IV subjects (95 % CI 25,638-35.09). the average
survival of subjects who received chemotherapy was 38.28 months (95% CI 33.44-43.11). not receiving adjuvant therapy was 33.71 months (95% CI 27.79-39.63).
Mean survival of subjects who received definitive surgery (44.39 months; 95% CI 40.35-48.43) and who did not get definitive surgery (20.08 months; 95% CI 15.8224.36).
Conclusion: The overall survival rate of the CC within five years at the RSCM was 43%. Factors that influence patient survival are clinical stage and definitive surgery
in primary tumor mass resection
Keywords: colorectal cancer, survival rate

Introduction
Colorectal cancer (CC) consisted of colon cancer and rectal cancer,
depending on where the tumor is found.1 The primary etiology of these
tumors was a combination of genetic and environmental factors. Most
CC spreads sporadically. About three-quarters of patients have no
previous family history. However, those with a family history and
diagnosed at age 50-70 are likely to risk developing cancer two folds.
Whereas when diagnosed at age <50 years, the first-degree family
members' risk increases to three folds. Such a risk increase for
individuals having more than a family member with CC.2,3
The classification is based on the stage, which is essential to determine
the treatment and prognosis. There are classification systems: the TNM
system, the most used classification in daily clinical practice, and the
Surveillance, Epidemiology, and End Results (SEER) systems. The
SEER classification is used for descriptive and statistical analysis for the
benefit of patient registration data.4 Another classification is the Duke
classification. According to Duke, CC commencing with epithelial
proliferation resulting in an adenoma. Cancer cells remain confined to
the rectal wall classified as Duke A. Should these cells progressed
beyond the rectum, classified as Duke B, and if metastasis occurred, then
classified as Duke C.

Table 1. Classification of tumors, nodes, and metastases in CC:5

T- Primary tumor
Tx The primary tumor cannot be assessed
T0 no sign of a primary tumor
Tis carcinoma in situ: intraepithelial tumor invasion or lamina propria
T1 tumor invasion into submucosa
T2 tumor invasion of propria muscularis
T3 tumor invasion through propria muscularis to the subserosa or to nonperitoneal tissue or perirectal tissue
T4 tumors directly invade other organs or structures and penetrate the
visceral peritoneum
N- Regional lymph nodes
NX Regional lymph node cannot be assessed
N0 there is no metastasis to regional lymph
N1 metastasis in 1 to 3 regional lymph nodes
N2 metastasis in 4 or more regional lymph nodes
M-metastasis is far away
Mx distant metastases cannot be assessed
M0 there is no distant metastasis
M1 is distant metastasis

13

The New Ropanasuri Journal of Surgery 2020 Volume 5 No.2:13–17.

Table 2. Classification of tumors according to TNM, Dukes,
and MAC
Stage
T
N
M Duke
MAC
0
Tis
N0 M0
I
T1
N0 M0
A
A
T2
N0 M0
A
B1
IIA
T3
N0 M0
B
B2
IIB
T4
N0 M0
B
B3
IIIA
T1, T2
N1 M0
C
C1
IIIB
T3, T4
N1 M0
C
C2/C3
IIIC
TAny
N2 M0
C
C1/C2/C3
IV
TAny NAny M1
D
D
Table 3. Duke classification and five-year survival
Stage classification
based on Duke criteria
A (stage I)
B (stage IIA and IIB)

C (stage IIIA-C)
D (s stage IV)

Description
Localized to the mucosa and
sub-mucosa
Extends to the muscular layer
without lymph node
involvement
Lymph node involvement
Distant metastasis

Five year
survival rate
(%)
93%
72%-85%

44%-83%
8%

Surgery is the primary treatment for CC with no metastasis. The
outcome depends on the quality of surgery, the stage, and further
therapy. In more severe cases, neoadjuvant therapy (such as
perioperative chemotherapy for T4 cancer lesions and [chemo]
radiotherapy for local lesions) may reduce tumor stage and increase
resection success.3
According to GLOBOCAN data in 2019, CC is the third most deadly
cancer and places the fourth rank as the most commonly diagnosed
cancer worldwide. There are two million new cases, and one million
patients died due to CC in 2019. The incidence of CC continually
increases every year, especially in developing countries. The reason why
developing countries because adopting the "western lifestyle." Obesity,
lack of physical activity, red meat consumption, alcohol, and tobacco are
risk factors for CC. Cumulative death risk of CC at the age of 0-74 years
is 0.66% in male and 0.44% in a female, with a mortality rate of 8.9 per
100,000 cases.2 The survival rate is the proportion of cancer patients who
can survive within a certain period after a cancer diagnosis is made. In
well-developed countries, the five-year life expectancy is more than
60%, but lower at <50% in Iran. In the United States, five-year life
expectancy for stage I is 92%, stage IIA and IIB 87%, 65%, stage IIIA,
and IIIB 90% and 72%, and stage IIIC 53%. In contrast, for metastasis,
only 12%.6
Most Indonesian come in an advanced stage; for many reasons such as
ignorance, cultural, social, and economic ones. The incidence in dr.
Cipto Mangunkusumo General Hospital (RSCM), as a referral center,
with a reasonably high as in Indonesia, is 8.6% (GLOBOCAN, 2018).
So far, the survival rate in the hospital remain unclear. Thus, we run a
study focus on this survival
Method
This study was a retrospective cohort design with survival rate analysis,
enrolling subjects diagnosed as CC managed in RSCM from January
2014 to December 2016. Data were taken from the cancer registration
in RSCM. Inclusion were those diagnosed and managed in the hospital.
Subjects’ characteristics, including age, gender, body mass index (BMI),
comorbid, family history, clinical stage, and therapy, were the focus of
interests subjected to analysis. Outcomes, particularly mortality within
five years, was the dependent variable. Survival analysis was carried out
using the log-rank test and Kaplan Meier curve showing the probability

of an event. The committee of ethic Faculty of Medicine, Universitas
Indonesia, approved the study.
Results
Out of 316 patients recorded from January 2014 to December 2016, 142
enrolled in the study.
Table 4. Subjects characteristics with colorectal cancer in RSCM 2014-2016
Clinical
n
%
Age
<45 years
38
26.8
≥45 years
104
73.2
Gender
Male
79
55.6
Female
63
44.4
Stage
II
22
15.5
III
46
32.4
IV
74
52.1
Surgery
Yes
94
66.2
No
48
33.8
Adjuvant Therapy
Without adjuvant therapy
49
34.5
Chemotherapy
78
54.9
Radiotherapy
3
2.1
Chemotherapy and radiotherapy 12
8.5
Five years survival rate
Survive
61
43.0
Non survive
81
57.0

Subjects predominated by males (55.6%) with the most age more than
45 years (73.2%), and of stage IV (52.1%). Out of these, 66.2%
underwent definitive surgery followed by adjuvant therapy, namely
chemotherapy (54.9%). Overall five-year survival in this study was
43%.
Table. 5 Log-rank tests and prognostic factors influencing the fiveyear survival
Non survive
Survive
Variable
p
(n = 81)
(n = 61)
Age
<45 years
20(52.6%) 18(47.4%) 0.463
≥45 years
61(58.7%) 43(41.3%)
Stage
Stage II
6(27.3%)
16(72.7%) 0.001
Stage III
23(28.4%) 23(50.0%)
Stage IV
52(64.2%) 22(29.7%)
Definitive Surgery
Yes
38(40.4%) 56(59.6%) 0.000
No
43(89.6%)
5(10.4%)
Adjuvant therapy
Without adjuvant
31(63.3%) 18(36.7%) 0.703
Chemotherapy
41(52.6%) 37(47.4%)
Chemotherapy and radiotherapy
7(58.3%)
5(41.7%)
Radiotherapy
2(66.7%)
1(33.3%)

In this study, the group of those of age ≥45 years, showing the most
group with high mortality with a five-year survival of 41.3%. However,
age was not significantly associated with survival (p = 0.521).
The Kaplan Meier showing up to 50% of those aged ≥45 years died
with 20 months. In contrast, those aged <45 years remained during
period observation of five years. The survival rate in those aged <45
14
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years was 38.9 months (95% CI 32.08-45.75) with a median of 36
months.

Subjects receiving chemotherapy showed a survival rate of 47.4%
among the other adjuvant therapy groups and those whose not receiving
adjuvant therapy. Compared with the group not receiving adjuvant
therapy (36.7%), those receiving radiotherapy showed a survival rate of
33.3%.
However, no significant difference between the group of adjuvant
therapy (both those receiving and not receiving adjuvant therapy) with
survival (p = 0.674).

Figure 1. Kaplan-Meier survival curve for the variable of age

Figure 4. Kaplan Meier survival curve based on adjuvant therapy

This study's overall survival rate was 36.17 months (95% CI 35.59639.756) with a median of 25 months. The survival rate of subjects
receiving chemotherapy was 38.28 months (95% CI 33.44-43.11). The
group's survival rate not receiving adjuvant therapy was 33.71 months
(95% CI 27.79-39.63). There was no significant association between
adjuvant therapy and survival (p = 0.703). Subjects receiving definitive
surgery showed the five-year survival rate of 59.6%.
Figure 2. Kaplan-Meier survival curve for variable of cancer stage

There was a significant association between stage and mortality (p =
0.001). The five-year survival rate ranges between 72.7% in stage II and
29.7% in stage IV.

Furthers, a significant differences showed between subjects receiving
definitive surgery compared to those not (p = 0,000) in the outcome.

Figure 5. Kaplan Meier survival curves based on definitive surgery
Figure 3. Kaplan-Meier survival curve by stadium

Overall survival in this study was 36.17 months (95% CI 32.59-39.75),
for stage II 50.68 months (95% CI 44.03-57.32), stage III 38.59 months
(95% CI 32.20-44.97), and stage IV 30.36 months (95% CI 25.63835.09).

The survival rate of subjects receiving definitive surgery was 44.39
months (95% CI 40.35-48.43), while subjects receiving no definitive
surgery was 20.08 months (95% CI 15.82-24.36).
On bivariate analysis, we found a significant association between stage
II (p = 0.002), stage IV (p = 0.001) and definitive treatment (p <0.001)
15
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with s mortality. In contrast, stage III no significant association (p =
0.241). Stage II showed a 23% likelihood of death than stage III and IV
(p = 0.002; CI 0.082-0.617). Subjects with stage IV showed a likelihood
of 3.2 times to death rather than other stages. Compared with subjects
not receiving definitive surgery, those receiving showed a reduced
likelihood of death by 79%.
Table 6. The survival rate
Variable

Non survive
(n = 81)

Survive
(n = 61)

Age
<45 years
20
18
≥45 years
61
43
Stage
Stage II
6
16
Stage III
23
23
Stage IV
52
22
Definitive surgery
Yes
38
56
No
43
5
Adjuvant Therapy
Without adjuvant
31
18
Chemotherapy
41
37
Chemotherapy and
7
5
radiotherapy
radiotherapy
2
1
HR: Hazard Ratio; CI: Confidence Interval

HR

CI 95%

p

1.27

(0.61-2.69)

0.521

0.23
0.66
3.18

(0.08-0.62)
(0.32-1.33)
(1.60-6.35)

0.002
0.241
0.001

0.79

(0.029-0.22)

0.000

1.48
0.67

(0.728-3.011)
(0.339-1.303)
(0.13517.147)
(0.319-3.514)

0.277
0.234

1.52
1.06

1.000
0.925

A multivariate analysis with logistic regression was carried out to find
the probability of survival in subjects exposed to all risk factors,
including those with p values <0.25 in bivariate analysis.
Table 7 Multivariate analysis of the five-year survival of the CRC.
Variable
HR
CI95%
Stage II
5.19
(1.524-17.692)
Stage III
3.72
(1.446-9.574)
Definitive surgery
11.70
(3.961-34.519)

p
0.008
0.006
0.000

It was found that only stage II, III, and those receiving definitive therapy
showed a significant association with the five–year survival.
Furthermore, we found stage II showing a 5.2-fold to live (p = 0.008; CI
1,524-17,692) compared to other stages, Subjects receiving definitive
surgery showing 11.7 times to live (p <0.001; CI 3.961-34.519)
compared to other variables.
Discussion
Of the 142 colorectal cancer patients included in this study, 43% of
patients survived until the observation period (5 years). Four main
factors were analyzed to find its effect on colorectal cancer survival,
namely age, clinical stage, definitive therapy, and adjuvant therapy.
Based on the analysis, subjects aged <45 years showed better five-year
survival (47.4% vs. 41.3%). However, we found no significant
difference between age and survival. Our findings differ from the study
by Chao-Hsien et al., which shows age is a predictor of survival and
prognosis in colorectal cancer.7
The subjects were mostly of stage IV (52.8%), whereas Chao-Hsien et
al., showing the majority were stage II and III. In this study, we noted
there were nine (6.3%) subjects aged under 30 years. It should be noted
that colorectal cancer is now found in the younger population and those
who may have symptoms but not included in the qualification screening
based on the American Cancer Society (ACS) to worsen the prognosis.
For this reason, targeting the screening to a younger population may
improve outcomes.7

In the present study, the higher stage, the higher the mortality found. The
five-year survival in stage II up to 72.7%; and dramatically fall to 29.7%
in stage IV. This study's finding consistent with the study by Joachim et
al., the more advanced when diagnosed, the higher mortality shown.8
Early–stage showed a better prognosis; in those with advanced stages,
cancer develops very progressively and aggressively, reducing
survival.9 Similar findings were reported by Ghazali et al. that showing
liver metastasis was a significant prognostic factor for survival (p
<0.001. Subjects with stage IV showing a risk of 6.7-times to death
compared with stage II, and those with liver metastasis showing a risk of
3.8-times to death than those without liver metastasis.10
The overall five-year survival rate in the present study was 43%, and
almost similar to other Southeast Asian countries, such as Malaysia
(45.4%), Thailand (42.45%), and the Philippines (44%).11 However,
Australia, Taiwan, and The United States of America showed a better
survival rate of 63%, 68.66%, and 64.9%, respectively.12,13 Most of the
population in Southeast Asian countries came in an advanced stage, as
reported by Phimha et al. in Thailand where 71.81% of patients admitted
were found in an advanced stage with insufficient screening programs
and awareness for early detection. The screening program in the United
States screening program commenced in 1960, and in Taiwan, the
program launched in 2004, reducing mortality in the first decade after
the program launched.14
Cox regression analysis showed that definitive surgery, which is tumor
resection significantly associated with better survival. Those receiving
resection showed a five-year survival of 59.6%, and those not were
10.4%. However, the overall survival rate in those receiving resection
was 44.39 months. This finding is similar to the study by Duraker et al.
showing a better survival rate in those receiving tumor resection.15
When we focused on the tumor staging, the analysis showed the risk of
mortality for stage IV 3.2 times to stage II and III. Those with stage II
and III showed a risk of 5.2 and 3.7 times, respectively, compared to
those with stage IV. Circulating tumor cells that are difficult to treat may
be responsible as the causal, even though radical dissection has been
carried out to control the tumor invasion locally. Thus, distant metastasis
(namely, stage IV) was the most risk of death.16
Comparing the prognosis of those receiving resection and not receiving
may lead to a bias in patient selection. Non-resection applied to those
with poor conditions in a more advanced case.17-19 A meta-analysis
shows that palliative tumor resection in asymptomatic and/or mild
symptomatic colorectal cancer patients with stage IV showed a better
survival as it reduces the risk of intestinal complications.20
Survival has not been associated with adjuvant therapy. The analysis
showed that those receiving adjuvant therapy were found to have better
survival (382 months; 95%CI 33.48-43.11). Papamichael et al. showed
that 5-Fluorouracil (5-FU)/Leucovorin (LV) intravenous leading to 29%
five–year mortality risk.38 Different regimens may responsible for the
different findings. Different characteristics, particularly those
predominated with stage IV (52.1%) in RSCM, may have a poor
prognosis.21
The consensus recommends surgical resection on those with locally
advanced completed with adequate lymphadenectomy followed by
adjuvant chemotherapy in those at risk of recurrence. The treatment
including local resection through transanal approach, plus total
mesorectal excision completed with neoadjuvant chemoradiotherapy in
locally advanced when diagnosed..21
Conclusion
The overall five–year survival of colorectal cancer was 43%.
Influencing factors are clinical stage and definitive surgery, namely
tumor resection
16
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